Peritonsillar AbscessNCT03326661
Peritonsillar Abscess: Aspiration Versus Tonsillectomy a Chaud
A study testing Aspiration, Tonsillectomy a chaud and Penicillin V + metronidazol (Penicillin allergy: Clindamycin alone) in people with Peritonsillar Abscess, run by Odense University Hospital at 1 site in Denmark.
Trial summary
Peritonsillar abscess (PTA) has a relatively high incidence of 41 per 100,000/year in Denmark. In spite of that, there is no regional or national consensus on treatment of PTA. Abscess drainage can be done by aspiration, incision or acute tonsillectomy. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Peritonsillar Abscess
- What is being tested?
- Aspiration, Tonsillectomy a chaud and Penicillin V + metronidazol (Penicillin allergy: Clindamycin alone)
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 128 participants
- Where
- 1 siteDenmark
- Study dates
- 10 Nov 2017to 30 Nov 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Peritonsillar abscess
Who cannot join
- respiratory distress
- suspected malignancy
- previous PTA
- history of recurrent tonsillitis
- patients with poor compliance to aspiration
Trial locations and contacts
1 site in 1 country.
Denmark1 site
Odense University Hospital
Odense, 5000
Daniel Skansing, +45 51932184, Daniel.Brauner.Skansing3@rsyd.dk
Christian Heidemann, 50937375, chrheidemann@gmail.com
About this study
Peritonsillar abscess (PTA) has a relatively high incidence of 41 per 100,000/year in Denmark. In spite of that, there is no regional or national consensus on treatment of PTA. Abscess drainage can be done by aspiration, incision or acute tonsillectomy. Several studies show that incision and aspiration are equally successful. The aim for this study is to compare aspiration to acute tonsillectomy (tonsillectomy a chaud) in a RCT study regarding sick-leave days, days of admission, pain, consumption of antibiotics, consumption of painkillers and patients´ self-assessed quality of life.
Read the detailed description
Background Peritonsillar abscess (PTA) is a complication of acute tonsillitis. The condition occurs when the infection spreads from the tonsil to the peritonsillar tissue, resulting in accumulation of pus between the tonsil and the muscles of the throat.
PTA is a common condition with an incidence of 41 per 100.000/year in Denmark. Untreated, PTA may develop into a potentially fatal condition with respiratory problems due to para- or retrofaryngeal abscess or spread of infection to surrounding tissue with necrotizing fasciitis, sepsis and thrombophlebitis of the jugular vein (Lemierres syndrome).
In spite of the high incidence of PTA, there is no regional or national consensus on the treatment of the PTA. There are several methods used for the treating of PTA. Draining of the abscess can be done by puncture and aspiration, incision or immediate abscess tonsillectomy (tonsillectomy a chaud). Additional treatment may consist of antibiotics, analgesics and rehydration. Depending on the general condition patients are either hospitalized for treatment or receive outpatient treatment (aspiration or incision).
Acute surgical intervention (tonsillectomy a chaud) is relevant in children, adults who cannot cooperate to aspiration, if malignancy is suspected in the patient, patients who experience insufficient effect from treatment with aspiration and antibiotics, patients with recurrent PTA or history of recurrent tonsillitis. Based on these criteria, a previous published article reported a relative indication for immediate abscess tonsillectomy in approximately 30% of patients with PTA. The advantage of surgery is that the abscess cavity cannot reform and that, in many cases, antibiotic treatment may be discontinued after the operation. The risk of surgery is primarily post-operative hemorrhage. The hemorrhage rate after immediate abscess tonsillectomy is not significantly higher compared to elective tonsillectomy.
Alternative treatment options are puncture and aspiration of pus or incision and dilatation. Benefits of these treatments are that the patient usually can be treated in outpatient clinics, and avoid surgery in general anesthesia. Good patient compliance is required as well as concomitant antibiotic treatment. Incision treatment has not been found more successful compared to aspiration treatment (NNT=48).
Several studies have compared immediate abscess tonsillectomy to puncture and aspiration and reported high success rates (82-95%) for aspiration. However, the risk of aspiration or incision is that the PTA will reform, necessitating subsequent tonsillectomy. The PTA reformation risk is highest in patients with a history of recurrent tonsillitis.
A prospective study including 53 patients hospitalized with PTA, has reported significantly shorter hospital stay for patients treated with tonsillectomy compared to aspiration, but no randomized studies have been conducted investigating differences in duration of hospital stay or days absent from work between treatments. Furthermore, there is a lack of studies investigating patient reported outcomes such af quality of life and satisfactionwith treatment.
The purpose of this study is to evaluate the effect of tonsillectomy a chaud versus needle aspiration for PTA. The primary outcome is number of sick-leave days and days spent in hospital. Secondary outcomes include consumption of antibiotics, consumption of painkillers, VAS score and patients' self-assessed quality of life in relation to treatment. The results of the study will improve information and advice given to patients with PTA as well as aid clinicians in choosing the best treatment.
Materials and Methods The study is designed as a prospective randomized non-blinded controlled multicenter trial. Patients will be enrolled from Departments of ENT-HNS in Southern Denmark. Inclusion criteria are adult patients (age 18 years or older) with PTA. Patients with respiratory distress, suspected malignancy, previous PTA, deep neck infection or history of recurrent tonsillitis and patients with poor compliance to aspiration will be excluded. Criteria are chosen based on current clinical guidelines.
PTA is defined by presence of pus, confirmed by 3-point aspiration. Aspiration can be performed under local anesthesia with xylocaine spray or injection of local anesthetic. Puncture and aspiration will be done from three predefined points. The patient is eligible for inclusion in the presence of pus and is randomized to either needle aspiration or tonsillectomy a chaud.
Patients treated with aspiration will receive standard antibiotic treatment according to clinical guidelines: Penicillin and metronidazole or Clindamycin alone in case of penicillin allergy. These patients will be treated in the outpatient clinic and will be examined again the day after inclusion. Aspiration will be done if necessary. At this first control visit the clinician will schedule the next visit based on findings.
Patients treated with tonsillectomy a chaud are admitted for intra-venous treatment with penicillin and metronidazole until surgery. Antibiotic treatment is discontinued after surgery and the patient may be discharged from the hospital the day after surgery.
Data will be collected regarding gender, age, history of tonsillitis (number of sore throats per year over the past 3 years) and regarding predefined outcomes: duration of hospital stay, duration of sick leave, use of antibiotics, VAS score and use of painkillers. The patient is also asked to indicate when he feels well again and free from disease. Quality of life will be measured using the Glasgow benefit Inventory which is validated for use in ENT-surgery. In addition, in the tonsillectomy group data regarding the number of episodes postoperative bleeding and readmissions will be collected and in the aspiration group data regarding the number of aspirations (outpatient controls) and number of rescue tonsillectomies due to failure of aspiration treatment will be collected.
All patients will be follow-up after 1 week, 2 weeks, 4 weeks and 3 months using online surveys.
The project has been approved by the The Regional Committees on Health Research Ethics for Southern Denmark and The Danish Data Protection Agency. Data is stored in SharePoint or RedCap and analyzed in STATA. Randomization was done by Sealed Envelope Ldt. 2017 (https://sealedenvelope.com/simple-randomiser/v1/lists [Accessed 6 Oct 2017]).
All enrolled patients will receive written information.
- Power calculation Power calculation was done in order to estimate the minimum number of patients to be included in the study. A default value of 0.80 was chosen. Calculations are based on the assumption of the minimum relevant clinical difference between the two types of treatment in terms of number of days of sick leave. Patients will be randomized in two groups of equal size. Based on similar studies the investigators expect normal/parametric distribution of the data with standard deviation of 6 and mean difference of 3 between the two groups. Based on these assumptions a minimum of 64 patients should be included in each group to reject the null hypothesis (that there is no difference in the number of sick leave days). Significance level is set at 0.05.
II. Statistics In case of normal distribution unpaired t-test will be applied. Non-parametric tests will be applied if data is non-normally distributed.
Quality of life data will be analyzed according to recommendations by the developers of the applied instrument.
Ethical aspects Both treatment options included in the study are well established and used in current treatment of PTA. Patients fulfilling any of the exclusion criteria will be offered tonsillectomy.
Written consent will be obtained from all patients after oral and written information about the study.
Impact on the daily function in the ENT departments Patients with PTA are usually referred to the ENT department from general practitioners, ENT doctors in private clinics, emergency departments etc. A smaller proportion is treated in ENT private clinics if the general condition of the patient is good. Therefore, ENT doctors in private clinics will be asked to refer all patients with PTA to hospital departments for inclusion in the study.
The study will not interfere significantly with daily functions in the departments. However, at first visit the clinician will inform patients orally and hand out written information on the study as well as obtain written consent.
Economy Funding may be applied for in relevant research Foundations e.g. OUH's Research Group, Independent research, Consultant Council at OUH and Maersk Foundation.
Perspectives The investigators expect to include a total of 128 patients divided into two groups during a period of 12 months. The number of included patients from the different departments will vary according to size and activity level. The investigators hope to obtain enough evidence for a clinical guideline on the treatment of PTA.
Results are expected to be published in an international journal.
- Conditions
- Peritonsillar Abscess
- Being tested
- Aspiration, Tonsillectomy a chaud, Penicillin V + metronidazol (Penicillin allergy: Clindamycin alone)
- Keywords
- Tonsillectomy, Aspiration, Quinsy
- Medical subject headings
- Peritonsillar Abscess
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AspirationProcedure or surgery
Also called Puncture
Needle aspiration of pus from the peritonsilar abscess
Tonsillectomy a chaudProcedure or surgery
Also called Tonsil removal
Removal of tonsil(s) due to peritonsillar abscess
Penicillin V + metronidazol (Penicillin allergy: Clindamycin alone)Drug
patients treated with aspiration will receive antibiotic treatment
| Study group | Role | What they receive |
|---|---|---|
| Needle aspiration | Active comparator | Patients treated with aspiration will receive standard antibiotic treatment according to clinical guidelines: Penicillin and metronidazole or Clindamycin alone in case of penicillin allergy. These patients will be treated in the outpatient clinic and will be examined again the day after inclusion. Aspiration will be done if necessary. At this first control visit the clinician will schedule the next visit based on findings. Receives: Procedure: Aspiration; Drug: Penicillin V + metronidazol (Penicillin allergy: Clindamycin alone) |
| Tonsillectomy a chaud | Active comparator | Patients treated with tonsillectomy a chaud are admitted for intra-venous treatment with penicillin and metronidazole until surgery. Antibiotic treatment is discontinued after surgery and the patient may be discharged from the hospital the day after surgery. Receives: Procedure: Tonsillectomy a chaud |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of sick-leave days
Days away from job/education or other daily activities due to disease and treatment
Measured: 3 months
Secondary outcomes (4)
Antibiotic consumption
number of days with antibiotic treatment
Measured: 3 months
Painkiller consumption
number of days with painkillers necessary
Measured: 3 months
VAS score
pain score
Measured: 3 months
Quality of life and satisfaction with treatment measured by GBI
patient reported outcome
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Oct 2017
- Study start10 Nov 2017 (estimated)
- Primary completion30 Nov 2019 (estimated)
- Study completion30 Nov 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Peritonsillar AbscessStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- patients randomized to treatment by needle aspiration or tonsillectomy a chaud
- Masking
- None (open label)
- Enrolment
- 128 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Odense University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Christian Heidemann, Odense University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03326661
- Sponsor's protocol ID
- 15/42959
- Other IDs
- S-20150156
- Status last verified
- Nov 2017
- First submitted
- 15 Mar 2017
- Last updated
- 9 Nov 2017
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Nov 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Peritonsillar Abscess: Aspiration Versus Tonsillectomy a Chaud
- ClinicalTrials.gov ID
- NCT03326661
- Acronym / sponsor ID
- 15/42959
- Conditions
- Peritonsillar Abscess
- Keywords
- Tonsillectomy, Aspiration, Quinsy
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 128 participants (estimated)
- Lead sponsor
- Odense University HospitalUniversity, hospital or other
- Study start
- 10 Nov 2017 (estimated)
- Primary completion
- 30 Nov 2019 (estimated)
- Study completion
- 30 Nov 2020 (estimated)
- First posted
- 31 Oct 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Peritonsillar abscess (PTA) has a relatively high incidence of 41 per 100,000/year in Denmark. In spite of that, there is no regional or national consensus on treatment of PTA. Abscess drainage can be done by aspiration, incision or acute tonsillectomy. Several studies show that incision and aspiration are equally successful. The aim for this study is to compare aspiration to acute tonsillectomy (tonsillectomy a chaud) in a RCT study regarding sick-leave days, days of admission, pain, consumption of antibiotics, consumption of painkillers and patients´ self-assessed quality of life.
Detailed description
Background Peritonsillar abscess (PTA) is a complication of acute tonsillitis. The condition occurs when the infection spreads from the tonsil to the peritonsillar tissue, resulting in accumulation of pus between the tonsil and the muscles of the throat.
PTA is a common condition with an incidence of 41 per 100.000/year in Denmark. Untreated, PTA may develop into a potentially fatal condition with respiratory problems due to para- or retrofaryngeal abscess or spread of infection to surrounding tissue with necrotizing fasciitis, sepsis and thrombophlebitis of the jugular vein (Lemierres syndrome).
In spite of the high incidence of PTA, there is no regional or national consensus on the treatment of the PTA. There are several methods used for the treating of PTA. Draining of the abscess can be done by puncture and aspiration, incision or immediate abscess tonsillectomy (tonsillectomy a chaud). Additional treatment may consist of antibiotics, analgesics and rehydration. Depending on the general condition patients are either hospitalized for treatment or receive outpatient treatment (aspiration or incision).
Acute surgical intervention (tonsillectomy a chaud) is relevant in children, adults who cannot cooperate to aspiration, if malignancy is suspected in the patient, patients who experience insufficient effect from treatment with aspiration and antibiotics, patients with recurrent PTA or history of recurrent tonsillitis. Based on these criteria, a previous published article reported a relative indication for immediate abscess tonsillectomy in approximately 30% of patients with PTA. The advantage of surgery is that the abscess cavity cannot reform and that, in many cases, antibiotic treatment may be discontinued after the operation. The risk of surgery is primarily post-operative hemorrhage. The hemorrhage rate after immediate abscess tonsillectomy is not significantly higher compared to elective tonsillectomy.
Alternative treatment options are puncture and aspiration of pus or incision and dilatation. Benefits of these treatments are that the patient usually can be treated in outpatient clinics, and avoid surgery in general anesthesia. Good patient compliance is required as well as concomitant antibiotic treatment. Incision treatment has not been found more successful compared to aspiration treatment (NNT=48).
Several studies have compared immediate abscess tonsillectomy to puncture and aspiration and reported high success rates (82-95%) for aspiration. However, the risk of aspiration or incision is that the PTA will reform, necessitating subsequent tonsillectomy. The PTA reformation risk is highest in patients with a history of recurrent tonsillitis.
A prospective study including 53 patients hospitalized with PTA, has reported significantly shorter hospital stay for patients treated with tonsillectomy compared to aspiration, but no randomized studies have been conducted investigating differences in duration of hospital stay or days absent from work between treatments. Furthermore, there is a lack of studies investigating patient reported outcomes such af quality of life and satisfactionwith treatment.
The purpose of this study is to evaluate the effect of tonsillectomy a chaud versus needle aspiration for PTA. The primary outcome is number of sick-leave days and days spent in hospital. Secondary outcomes include consumption of antibiotics, consumption of painkillers, VAS score and patients' self-assessed quality of life in relation to treatment. The results of the study will improve information and advice given to patients with PTA as well as aid clinicians in choosing the best treatment.
Materials and Methods The study is designed as a prospective randomized non-blinded controlled multicenter trial. Patients will be enrolled from Departments of ENT-HNS in Southern Denmark. Inclusion criteria are adult patients (age 18 years or older) with PTA. Patients with respiratory distress, suspected malignancy, previous PTA, deep neck infection or history of recurrent tonsillitis and patients with poor compliance to aspiration will be excluded. Criteria are chosen based on current clinical guidelines.
PTA is defined by presence of pus, confirmed by 3-point aspiration. Aspiration can be performed under local anesthesia with xylocaine spray or injection of local anesthetic. Puncture and aspiration will be done from three predefined points. The patient is eligible for inclusion in the presence of pus and is randomized to either needle aspiration or tonsillectomy a chaud.
Patients treated with aspiration will receive standard antibiotic treatment according to clinical guidelines: Penicillin and metronidazole or Clindamycin alone in case of penicillin allergy. These patients will be treated in the outpatient clinic and will be examined again the day after inclusion. Aspiration will be done if necessary. At this first control visit the clinician will schedule the next visit based on findings.
Patients treated with tonsillectomy a chaud are admitted for intra-venous treatment with penicillin and metronidazole until surgery. Antibiotic treatment is discontinued after surgery and the patient may be discharged from the hospital the day after surgery.
Data will be collected regarding gender, age, history of tonsillitis (number of sore throats per year over the past 3 years) and regarding predefined outcomes: duration of hospital stay, duration of sick leave, use of antibiotics, VAS score and use of painkillers. The patient is also asked to indicate when he feels well again and free from disease. Quality of life will be measured using the Glasgow benefit Inventory which is validated for use in ENT-surgery. In addition, in the tonsillectomy group data regarding the number of episodes postoperative bleeding and readmissions will be collected and in the aspiration group data regarding the number of aspirations (outpatient controls) and number of rescue tonsillectomies due to failure of aspiration treatment will be collected.
All patients will be follow-up after 1 week, 2 weeks, 4 weeks and 3 months using online surveys.
The project has been approved by the The Regional Committees on Health Research Ethics for Southern Denmark and The Danish Data Protection Agency. Data is stored in SharePoint or RedCap and analyzed in STATA. Randomization was done by Sealed Envelope Ldt. 2017 (https://sealedenvelope.com/simple-randomiser/v1/lists [Accessed 6 Oct 2017]).
All enrolled patients will receive written information.
- Power calculation Power calculation was done in order to estimate the minimum number of patients to be included in the study. A default value of 0.80 was chosen. Calculations are based on the assumption of the minimum relevant clinical difference between the two types of treatment in terms of number of days of sick leave. Patients will be randomized in two groups of equal size. Based on similar studies the investigators expect normal/parametric distribution of the data with standard deviation of 6 and mean difference of 3 between the two groups. Based on these assumptions a minimum of 64 patients should be included in each group to reject the null hypothesis (that there is no difference in the number of sick leave days). Significance level is set at 0.05.
II. Statistics In case of normal distribution unpaired t-test will be applied. Non-parametric tests will be applied if data is non-normally distributed.
Quality of life data will be analyzed according to recommendations by the developers of the applied instrument.
Ethical aspects Both treatment options included in the study are well established and used in current treatment of PTA. Patients fulfilling any of the exclusion criteria will be offered tonsillectomy.
Written consent will be obtained from all patients after oral and written information about the study.
Impact on the daily function in the ENT departments Patients with PTA are usually referred to the ENT department from general practitioners, ENT doctors in private clinics, emergency departments etc. A smaller proportion is treated in ENT private clinics if the general condition of the patient is good. Therefore, ENT doctors in private clinics will be asked to refer all patients with PTA to hospital departments for inclusion in the study.
The study will not interfere significantly with daily functions in the departments. However, at first visit the clinician will inform patients orally and hand out written information on the study as well as obtain written consent.
Economy Funding may be applied for in relevant research Foundations e.g. OUH's Research Group, Independent research, Consultant Council at OUH and Maersk Foundation.
Perspectives The investigators expect to include a total of 128 patients divided into two groups during a period of 12 months. The number of included patients from the different departments will vary according to size and activity level. The investigators hope to obtain enough evidence for a clinical guideline on the treatment of PTA.
Results are expected to be published in an international journal.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- patients randomized to treatment by needle aspiration or tonsillectomy a chaud
| Arm | Type | Receives |
|---|---|---|
| Needle aspiration | Active comparator | Procedure: Aspiration, Drug: Penicillin V + metronidazol (Penicillin allergy: Clindamycin alone)Patients treated with aspiration will receive standard antibiotic treatment according to clinical guidelines: Penicillin and metronidazole or Clindamycin alone in case of penicillin allergy. These patients will be treated in the outpatient clinic and will be examined again the day after inclusion. Aspiration will be done if necessary. At this first control visit the clinician will schedule the next visit based on findings. |
| Tonsillectomy a chaud | Active comparator | Procedure: Tonsillectomy a chaudPatients treated with tonsillectomy a chaud are admitted for intra-venous treatment with penicillin and metronidazole until surgery. Antibiotic treatment is discontinued after surgery and the patient may be discharged from the hospital the day after surgery. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Peritonsillar abscess
Key exclusion criteria (5 listed)
- respiratory distress
- suspected malignancy
- previous PTA
- history of recurrent tonsillitis
- patients with poor compliance to aspiration
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AspirationAlso: PunctureNeedle aspiration of pus from the peritonsilar abscess | Procedure or surgery | Needle aspiration |
| Tonsillectomy a chaudAlso: Tonsil removalRemoval of tonsil(s) due to peritonsillar abscess | Procedure or surgery | Tonsillectomy a chaud |
| Penicillin V + metronidazol (Penicillin allergy: Clindamycin alone)patients treated with aspiration will receive antibiotic treatment | Drug | Needle aspiration |
Primary outcome
Number of sick-leave days
Time frame: 3 months
Days away from job/education or other daily activities due to disease and treatment
4 secondary outcomes
Antibiotic consumption
Time frame: 3 months
Painkiller consumption
Time frame: 3 months
VAS score
Time frame: 3 months
Quality of life and satisfaction with treatment measured by GBI
Time frame: 3 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Nov 2017.
- Individual participant dataSharing planned: No
Related trials for Peritonsillar Abscess
Not yet recruitingPhase 4
A Single Dose of Intravenous Penicillin as an Adjunct to Oral Penicillin in the Treatment of Acute Tonsillitis, Peritonsillar Phlegmon, and Peritonsillar Abscess
Acute Tonsillitis, Peritonsillar Abscess
Recruiting
Transoral Ultrasound Versus no Transoral Ultrasound in Diagnostic Workup of Peritonsillar Abscess
Peritonsillar Abscess, Peritonsillar Cellulitis
RecruitingPhase 4
Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections
Methicillin Resistant Staphylococcus Aureus, Osteomyelitis Acute
RecruitingObservational study
Complicated Infections in Otorhinolaryngology
Sinusitis, Otitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Aspiration, Tonsillectomy a chaud and Penicillin V + metronidazol (Penicillin allergy: Clindamycin alone) in people with Peritonsillar Abscess, run by Odense University Hospital at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 9 Nov 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Daniel Skansing (+45 51932184, Daniel.Brauner.Skansing3@rsyd.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of sick-leave days (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Nov 2017.